Merck & Company Inc (MRK)vsVBI Vaccines Inc (VBIV)
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
VBIV
VBI Vaccines Inc
$0.07
0.00%
HEALTHCARE · Cap: $1.87M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 707253% more annual revenue ($66.57B vs $9.41M). MRK leads profitability with a 4.8% profit margin vs 0.0%. VBIV earns a higher WallStSmart Score of 40/100 (D).
MRK
Hold36
out of 100
Grade: F
VBIV
Hold40
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Intrinsic value data unavailable for VBIV.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Revenue surging 150.3% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : VBIV
The strongest argument for VBIV centers on Revenue Growth, Debt/Equity. Revenue growth of 150.3% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : VBIV
The primary concerns for VBIV are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
MRK profiles as a value stock while VBIV is a hypergrowth play — different risk/reward profiles.
VBIV carries more volatility with a beta of 2.17 — expect wider price swings.
VBIV is growing revenue faster at 150.3% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
VBIV scores higher overall (40/100 vs 36/100) and 150.3% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →VBI Vaccines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company is headquartered in Cambridge, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?